UroGen Pharma (URGN) News Today $11.40 -0.50 (-4.20%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$11.48 +0.08 (+0.70%) As of 08:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Rosalind Advisors Inc. Makes New $9.27 Million Investment in UroGen Pharma Ltd. (NASDAQ:URGN)Rosalind Advisors Inc. purchased a new stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 870,000 shares of the company's stock, valued at approximatMarch 23 at 5:48 AM | marketbeat.comUroGen Pharma (NASDAQ:URGN) Stock Price Up 3.6% - Time to Buy?UroGen Pharma (NASDAQ:URGN) Trading 3.6% Higher - Still a Buy?March 21, 2025 | marketbeat.comPrivium Fund Management B.V. Purchases Shares of 27,691 UroGen Pharma Ltd. (NASDAQ:URGN)Privium Fund Management B.V. acquired a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 27,691 shares of the company's stock, valued at approximately $295,March 20, 2025 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Receives $38.20 Consensus Price Target from BrokeragesMarch 19, 2025 | americanbankingnews.comUroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of "Buy" from AnalystsUroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) has received a consensus rating of "Buy" from the six brokerages that are currently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the compaMarch 16, 2025 | marketbeat.comHC Wainwright Reduces Earnings Estimates for UroGen PharmaUroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - Analysts at HC Wainwright lowered their Q1 2025 EPS estimates for shares of UroGen Pharma in a research note issued on Tuesday, March 11th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.93) per share for the quarter,March 14, 2025 | marketbeat.comHC Wainwright Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $55.00HC Wainwright dropped their price objective on UroGen Pharma from $64.00 to $55.00 and set a "buy" rating for the company in a report on Tuesday.March 12, 2025 | marketbeat.com34,701 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Purchased by Bender Robert & AssociatesBender Robert & Associates purchased a new stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 34,701 shares of the company's stock, valued at approximately $370,000. Bender Robert & AssoMarch 12, 2025 | marketbeat.comUroGen Pharma price target lowered to $55 from $64 at H.C. WainwrightMarch 11, 2025 | markets.businessinsider.comUroGen Pharma Ltd. (NASDAQ:URGN) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | insidermonkey.comUroGen Pharma sees FY25 operating expenses $215M-$225MMarch 10, 2025 | markets.businessinsider.comUrogen pharma outlines $1B revenue potential for UGN-102 with June 2025 launch targetMarch 10, 2025 | msn.comUroGen Pharma Ltd. (URGN) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | seekingalpha.comUroGen Pharma's (URGN) "Buy" Rating Reiterated at D. Boral CapitalD. Boral Capital reissued a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a research note on Monday.March 10, 2025 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Issues Quarterly Earnings ResultsUroGen Pharma (NASDAQ:URGN - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11).March 10, 2025 | marketbeat.comUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 7, 2025 | businesswire.comUroGen Pharma (URGN) to Release Earnings on ThursdayUroGen Pharma (NASDAQ:URGN) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=671541)March 6, 2025 | marketbeat.comUroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025February 27, 2025 | businesswire.comIs UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?February 26, 2025 | insidermonkey.comUroGen Pharma (NASDAQ:URGN) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $64.00 price objective on shares of UroGen Pharma in a report on Tuesday.February 25, 2025 | marketbeat.comUroGen Pharma to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | uk.finance.yahoo.comUroGen Pharma transferred with Buy rating at LadenburgFebruary 20, 2025 | markets.businessinsider.comUroGen expands cancer portfolio with IconOVir dealFebruary 20, 2025 | msn.comUroGen Pharma (NASDAQ:URGN) Earns Buy Rating from Analysts at LADENBURG THALM/SH SHLADENBURG THALM/SH SH began coverage on UroGen Pharma in a research note on Wednesday. They issued a "buy" rating and a $31.00 price target on the stock.February 20, 2025 | marketbeat.comD. Boral Capital Reiterates "Buy" Rating for UroGen Pharma (NASDAQ:URGN)D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Tuesday.February 19, 2025 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Rating of "Buy" from AnalystsShares of UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) have been assigned an average rating of "Buy" from the six research firms that are presently covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has given a stroFebruary 19, 2025 | marketbeat.comUroGen announces results from subgroup analyses of ENVISION trialFebruary 14, 2025 | markets.businessinsider.comUroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102February 14, 2025 | businesswire.comJELMYTO shows long-term effectiveness in cancer studyFebruary 12, 2025 | msn.comUroGen Pharma announces results from long-term Jelmyto follow-up studyFebruary 12, 2025 | markets.businessinsider.comUroGen Pharma's (URGN) Buy Rating Reaffirmed at D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and set a $25.00 target price on shares of UroGen Pharma in a research note on Wednesday.February 12, 2025 | marketbeat.comInsider Selling: UroGen Pharma Ltd. (NASDAQ:URGN) Insider Sells 4,551 Shares of StockFebruary 5, 2025 | insidertrades.comUrogen Pharma's general counsel sells $82,202 in sharesFebruary 4, 2025 | msn.comUroGen Pharma's chief medical officer sells shares worth $50,698February 4, 2025 | msn.comUroGen Pharma Ltd. (NASDAQ:URGN) Insider Mark Schoenberg Sells 4,551 SharesUroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now directly owns 145,666 shares of the company's stock, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.February 4, 2025 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) General Counsel Sells $82,202.06 in StockUroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) General Counsel Jason Drew Smith sold 7,379 shares of the company's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the transaction, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.February 4, 2025 | marketbeat.comUroGen: Upcoming PDUFA, Some Concerns RemainJanuary 31, 2025 | seekingalpha.comJPMorgan Chase & Co. Has $864,000 Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)JPMorgan Chase & Co. lifted its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 263.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 68,062 shares of the company's stock after buyingJanuary 26, 2025 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Rating of "Buy" from BrokeragesShares of UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) have been given an average recommendation of "Buy" by the six research firms that are presently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buJanuary 25, 2025 | marketbeat.comUroGen Pharma's (URGN) "Buy" Rating Reaffirmed at D. Boral CapitalD. Boral Capital restated a "buy" rating and issued a $25.00 target price on shares of UroGen Pharma in a research note on Thursday.January 23, 2025 | marketbeat.comJELMYTO shows promise in long-term cancer treatment studyJanuary 22, 2025 | msn.comBarclays PLC Increases Stake in UroGen Pharma Ltd. (NASDAQ:URGN)Barclays PLC grew its position in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 409.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,778 shares of the company's stock after acquiring an additional 48January 16, 2025 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at D. Boral CapitalD. Boral Capital restated a "buy" rating and issued a $25.00 price objective on shares of UroGen Pharma in a report on Wednesday.January 15, 2025 | marketbeat.comUroGen Pharma Highlights RTGel® Platform and Growth PlansJanuary 14, 2025 | tipranks.comBarclays PLC Has $759,000 Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)Barclays PLC raised its position in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 409.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 59,778 shares of the company's stock after purchasing an additional 48,040 shares during the period. Barclays PLC oJanuary 1, 2025 | marketbeat.comBreakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)December 31, 2024 | finance.yahoo.comUroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of "Buy" from BrokeragesShares of UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) have been assigned an average rating of "Buy" from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recoDecember 31, 2024 | marketbeat.comPoint72 Asset Management L.P. Trims Stake in UroGen Pharma Ltd. (NASDAQ:URGN)Point72 Asset Management L.P. cut its position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 38.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,506,646 shares of the company's stock after sellDecember 7, 2024 | marketbeat.comD. Boral Capital Reiterates Buy Rating for UroGen Pharma (NASDAQ:URGN)D. Boral Capital reiterated a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a research report on Friday.December 6, 2024 | marketbeat.comLong-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®December 5, 2024 | businesswire.com Remove Ads Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address URGN Media Mentions By Week URGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. URGN News Sentiment▼0.880.79▲Average Medical News Sentiment URGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. URGN Articles This Week▼43▲URGN Articles Average Week Remove Ads Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Centessa Pharmaceuticals News Today Kymera Therapeutics News Today CG Oncology News Today Denali Therapeutics News Today Belite Bio News Today Arrowhead Pharmaceuticals News Today Arcutis Biotherapeutics News Today Tarsus Pharmaceuticals News Today Harmony Biosciences News Today Travere Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:URGN) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy URGN Stock Free URGN Stock Alerts